ALTAltimmune, Inc.

$353M

Q2 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$6,000-25.0% YoY

Gross Profit

-$13M-220783.3% margin

Operating Income

-$18M-300116.7% margin

Net Income

-$16M-267683.3% margin

EPS (Diluted)

$-0.32

QoQ Revenue Growth

-71.4%

Cash Flow

Operating Cash Flow

-$20M

Free Cash Flow

-$20M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$183M

Total Liabilities

$16M

Stockholders' Equity

$168M

Cash & Equivalents

$102M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$6,000	$8,000	-25.0%
Gross Profit	-$13M	$8,000	-165687.5%
Operating Income	-$18M	-$20M	+11.7%
Net Income	-$16M	-$20M	+20.1%

ALT Q2 2023 Earnings — Altimmune, Inc. Revenue & Financial Results | Market Cap Arena